We combine access to multiple antibody discovery and development technologies with intellectual property, technical expertise and know-how, and integrated infrastructure to gain a unique advantage in the rapid and efficient development of fully human therapeutic antibodies with unique differentiating properties.
Our innovations include multiple antibody discovery and development technologies that position XOMA as an ideal antibody discovery and development partner:
|ADAPT™ (Antibody Discovery Advanced Platform Technologies): proprietary phage display libraries, seamlessly integrated with yeast and mammalian display to enable antibody discovery|
|ModulX™: technology that enables the modulation of biological pathway(s) using monoclonal antibodies|
|OptimX™: Human Engineering™ (HE™) and Target Affinity Enhancement (TAE™) technologies that are used for optimizing biophysical properties of antibodies, including affinity, immunogenicity, stability, and manufacturability|